JNJ vs ABBV
JNJ and ABBV side by side — valuation & fundamentals (public data).
Key statistics
| Metric | JNJJohnson & Johnson | ABBVAbbVie Inc. |
|---|---|---|
| Market cap | $657.80B | $520.97B |
| P/E (TTM) | 41.5 | 83.3 |
| P/B | 8.07 | — |
| P/S | 7.0x | 8.5x |
| Dividend yield | 1.88% | 2.24% |
| Revenue | $99.33B(TTM) | $61.16B(TTM) |
| Revenue growth (YoY) | 6.0% | 8.6% |
| Net income | $16.09B(TTM) | $6.31B(TTM) |
| Earnings growth (YoY) | 90.6% | -1.2% |
| EPS, diluted | $6.58(TTM) | $3.54(TTM) |
| EBIT margin | 22.9% | 24.6% |
| ROE | 32.9% | — |
| ROIC | 16.3% | 18.6% |
| Piotroski F | 6/9 | — |
| 1y total return | +47.3% | +32.0% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: JNJ vs ABBV
| Metric | JNJ | ABBV |
|---|---|---|
| End value | $30.2K | $73.0K |
| Total return | +202.5% | +629.9% |
| CAGR | +11.3% | +21.2% |
| Volatility | 18.8% | 25.8% |
| Sharpe | 0.44 | 0.72 |
| Sortino | 0.63 | 1.00 |
| Max drawdown | -27.4% | -45.1% |
Based on 2600 common trading days, 2016-06-29 → 2026-10-30 · risk-free 4.16% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)